Revvity (RVTY) Scheduled to Post Quarterly Earnings on Monday

Revvity (NYSE:RVTY) will post its quarterly earnings results before the market opens on Monday, November 4th. Analysts expect Revvity to post earnings of $1.13 per share for the quarter. Individual that are interested in participating in the company’s earnings conference call can do so using this link.

Revvity Trading Up 2.1 %

NYSE RVTY opened at $121.04 on Friday. The company has a current ratio of 2.27, a quick ratio of 1.98 and a debt-to-equity ratio of 0.40. Revvity has a 1-year low of $82.17 and a 1-year high of $128.15. The firm’s fifty day simple moving average is $121.39 and its 200-day simple moving average is $114.02. The company has a market capitalization of $14.93 billion, a PE ratio of 87.71, a price-to-earnings-growth ratio of 3.31 and a beta of 1.05.

Revvity Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, February 7th. Shareholders of record on Friday, January 17th will be given a $0.07 dividend. This represents a $0.28 annualized dividend and a yield of 0.23%. The ex-dividend date is Friday, January 17th. Revvity’s payout ratio is currently 20.29%.

Insider Buying and Selling

In other news, insider Tajinder S. Vohra sold 2,153 shares of the stock in a transaction that occurred on Monday, October 7th. The stock was sold at an average price of $122.09, for a total value of $262,859.77. Following the completion of the sale, the insider now directly owns 23,960 shares of the company’s stock, valued at approximately $2,925,276.40. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In other news, insider Tajinder S. Vohra sold 2,153 shares of the business’s stock in a transaction dated Monday, October 7th. The shares were sold at an average price of $122.09, for a total transaction of $262,859.77. Following the transaction, the insider now owns 23,960 shares in the company, valued at approximately $2,925,276.40. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, insider Tajinder S. Vohra sold 2,154 shares of the stock in a transaction dated Wednesday, October 9th. The shares were sold at an average price of $121.73, for a total transaction of $262,206.42. Following the completion of the sale, the insider now owns 19,652 shares of the company’s stock, valued at approximately $2,392,237.96. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 7,807 shares of company stock valued at $937,576. Insiders own 0.60% of the company’s stock.

Wall Street Analyst Weigh In

Several equities research analysts recently commented on the company. Leerink Partnrs raised Revvity to a “strong-buy” rating in a research note on Monday, July 8th. TD Cowen boosted their target price on shares of Revvity from $130.00 to $141.00 and gave the stock a “buy” rating in a research report on Tuesday, July 30th. Bank of America raised their price target on shares of Revvity from $118.00 to $127.00 and gave the company a “neutral” rating in a report on Tuesday, July 30th. JPMorgan Chase & Co. upped their price objective on shares of Revvity from $105.00 to $120.00 and gave the stock a “neutral” rating in a report on Tuesday, July 30th. Finally, Citigroup raised their target price on Revvity from $135.00 to $145.00 and gave the company a “buy” rating in a report on Tuesday, July 30th. Seven equities research analysts have rated the stock with a hold rating, eight have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat.com, Revvity has an average rating of “Moderate Buy” and an average target price of $128.79.

Revvity Company Profile

Revvity, Inc provides health sciences solutions, technologies, and services in the Americas, Europe, and Asia, and internationally. The Life Sciences segment provides instruments, reagents, informatics, software, subscriptions, detection, imaging technologies, warranties, training, and services. Its Diagnostics segment provides instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market.